M
Michael Meister
Researcher at University Hospital Heidelberg
Publications - 55
Citations - 1618
Michael Meister is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Lung cancer & Adenocarcinoma. The author has an hindex of 20, co-authored 55 publications receiving 1179 citations.
Papers
More filters
Journal ArticleDOI
Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles
Eyra Marien,Michael Meister,Thomas Muley,Steffen Fieuws,Sergio Bordel,Rita Derua,Jeffrey M. Spraggins,Raf Van de Plas,Raf Van de Plas,Jonas Dehairs,Jens Wouters,Muralidhararao Bagadi,Hendrik Dienemann,Michael Thomas,Philipp A. Schnabel,Richard M. Caprioli,Etienne Waelkens,Johannes V. Swinnen +17 more
TL;DR: Using both shotgun and 2D‐imaging lipidomics analysis, a hitherto unrecognized alteration in phospholipid profiles in NSCLC is uncovered, which may have important biological implications and may have significant potential for biomarker development.
Journal ArticleDOI
Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role
Arne Warth,Judith Cortis,Alex Soltermann,Michael Meister,Jan Budczies,Albrecht Stenzinger,Benjamin Goeppert,Michael Thomas,Felix J.F. Herth,Peter Schirmacher,Philipp A. Schnabel,Hans Hoffmann,Hendrik Dienemann,Thomas Muley,Wilko Weichert +14 more
TL;DR: The data demonstrate that PI is a clinically meaningful biomarker in NSCLC with entity-dependent cut-off values that allow reliable estimation of prognosis and may potentially stratify ADC patients for the need of adjuvant therapy.
Journal ArticleDOI
AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients
Marc A. Schneider,Petros Christopoulos,Thomas Muley,Arne Warth,Ursula Klingmueller,Michael Thomas,Felix J.F. Herth,Hendrik Dienemann,Nikola S. Mueller,Fabian J. Theis,Michael Meister +10 more
TL;DR: The data demonstrate that the expression of the mitosis-associated genes AURKA, DLGAP5, TPX2, KIF11 and CKAP5 is associated with the prognosis of NSCLC patients.
Journal ArticleDOI
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK + non-small cell lung cancer
Petros Christopoulos,Volker Endris,Farastuk Bozorgmehr,M. Elsayed,Martina Kirchner,J. Ristau,Ivo Buchhalter,Roland Penzel,Felix J.F. Herth,C.P. Heussel,Martin E. Eichhorn,Thomas Muley,Michael Meister,Jürgen Fischer,Stefan Rieken,Arne Warth,Helge Bischoff,Peter Schirmacher,Albrecht Stenzinger,Michael Thomas +19 more
TL;DR: Determination of V3 status should be considered as part of the initial workup for this entity in order to select patients for more aggressive surveillance and treatment strategies.
Journal ArticleDOI
Validation of a blood protein signature for non-small cell lung cancer
Michael R. Mehan,Stephen A. Williams,Jill M. Siegfried,Jill M. Siegfried,William L. Bigbee,Joel L. Weissfeld,David O. Wilson,Harvey I. Pass,William N. Rom,Thomas Muley,Michael Meister,Wilbur A. Franklin,York E. Miller,York E. Miller,Edward N. Brody,Rachel Ostroff +15 more
TL;DR: Selecting biomarkers resistant to sample processing variation led to robust lung cancer biomarkers that performed consistently in independent validations, including squamous cell histology.